Psychometric Characteristics of the Persian Version of the Opiate Dosage Adequacy Scale (ODAS)

Introduction: The opiate dosage adequacy scale (ODAS) is one of the most common assessment tools in studies on substance use disorders, which evaluates the “adequacy” of opiate medication doses in individuals recruited in maintenance approaches. There is no investigation on the Persian version of this questionnaire in Iran. This research validated a Persian version of the ODAS. Methods: The Persian version of the ODAS was translated and revised based on the original scale presented by González-Saiz et al. The psychometric characteristics of the ODAS were assessed via direct interviews. Three trained interviewers questioned 250 patients treated in methadone maintenance clinics in Mazandaran Province (Northern Iran) for more than three months. Internal consistency and factor analysis were conducted using SPSS software, version 24. Results: The internal consistency of ODAS was satisfactory (Cronbach’s α=0.81). Across all items, considerable inter-rater reliability was discovered (kappa values between 0.90 and 1). A four-component structure was produced by the factor analysis that accounted for 77.5% of the total variance. Cronbach’s α coefficients of the four components of Heroin craving and overmedication, Consumption, objective opiate withdrawal symptoms, and subjective opiate withdrawal symptoms were 0.84, 0.91, 0.83, and 0.74, respectively. Conclusion: The reliability and validity of the Persian version of the ODAS were satisfactory in a sample of methadone maintenance subjects.

[1]  K. Wenzel,et al.  Sex-based differences in psychiatric symptoms and opioid abstinence during buprenorphine/naloxone treatment in adolescents with opioid use disorders. , 2021, Journal of substance abuse treatment.

[2]  F. Altice,et al.  The Real-World Impact of Dosing of Methadone and Buprenorphine on Retention on Opioid Agonist Therapies in Ukraine. , 2020, Addiction.

[3]  J. Bruneau,et al.  The authors respond to “Opioid agonist dosage adequacy from clinical and patient perspectives: further considerations” , 2019, Canadian Medical Association Journal.

[4]  J. Trujols,et al.  Opioid agonist dosage adequacy from clinical and patient perspectives: further considerations , 2019, Canadian Medical Association Journal.

[5]  Nanor Minoyan,et al.  Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs , 2019, Canadian Medical Association Journal.

[6]  F. González-Saiz,et al.  Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment. , 2018, Drug and alcohol dependence.

[7]  I. Ojanperä,et al.  Polydrug abuse among opioid maintenance treatment patients is related to inadequate dose of maintenance treatment medicine , 2017, BMC Psychiatry.

[8]  S. Durán-Sindreu,et al.  Patient perception of methadone dose adequacy in methadone maintenance treatment: The role of perceived participation in dosage decisions. , 2017, Patient education and counseling.

[9]  A. Rahimi-Movaghar,et al.  Epidemiology of illicit drug use disorders in Iran: prevalence, correlates, comorbidity and service utilization results from the Iranian Mental Health Survey. , 2016, Addiction.

[10]  J. Trujols,et al.  Methadone maintenance treatment: the need to distinguish between holding dose, dose adequacy, satisfaction with methadone as a medication, and satisfaction with treatment. , 2010, Journal of clinical psychopharmacology.

[11]  Arrastus Attarad,et al.  Correlates of injection use of synthetic drugs among drug users in Pakistan: a case controlled study. , 2006, JPMA. The Journal of the Pakistan Medical Association.

[12]  K. Humphreys,et al.  Determining Effective Methadone Doses for Individual Opioid-Dependent Patients , 2006, PLoS medicine.

[13]  W. Ling,et al.  Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. , 2003, The New England journal of medicine.

[14]  H. W. Clark,et al.  Office-based practice and opioid-use disorders. , 2003, The New England journal of medicine.

[15]  J. White,et al.  Patterns of symptom complaints in methadone maintenance patients. , 1997, Addiction.

[16]  G. Woody,et al.  The Effects of Psychosocial Services in Substance Abuse Treatment , 1993, JAMA.

[17]  W. S. Condelli Strategies for increasing retention in methadone programs. , 1993, Journal of psychoactive drugs.

[18]  D. Metzger,et al.  The Fifth Edition of the Addiction Severity Index. , 1992, Journal of substance abuse treatment.

[19]  W K Bickel,et al.  Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. , 1988, The Journal of pharmacology and experimental therapeutics.

[20]  H. Kaiser A second generation little jiffy , 1970 .

[21]  Jacob Cohen A Coefficient of Agreement for Nominal Scales , 1960 .

[22]  M. Krausz,et al.  HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS , 2002 .

[23]  D. Cicchetti Guidelines, Criteria, and Rules of Thumb for Evaluating Normed and Standardized Assessment Instruments in Psychology. , 1994 .

[24]  D. Kleinbaum,et al.  Clinic policy and retention in methadone maintenance. , 1993, The International journal of the addictions.

[25]  G. Dunteman,et al.  Exposure to methadone programs and heroin use. , 1993, The American journal of drug and alcohol abuse.